

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/748,096
Filing Date	December 30, 2003
First Named Inventor	Doddabele L. Madhavi
Art Unit	1623
Examiner Name	Matthew L. Fedowitz
Attorney Docket Number	BIO 2-013


Sheet	1	of	4
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
		<del>EP1174109</del>	<del>01-23-2003</del>	<del>Nielsen, et al</del>		
		<del>JP56108590</del>	<del>08-31-1981</del>	<del>Yonezawa, et al</del>		

Examiner Signature		Date Considered	9/30/05
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/748,096
		Filing Date	December 30, 2003
		First Named Inventor	Doddabele L. Madhavi
		Art Unit	1623
		Examiner Name	Matthew L. Fedowitz
Sheet 2	of 4	Attorney Docket Number	BIO 2-013

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	"Accumulation and retention of micellar b-carotene and lutein by Caco-2 human intestinal cells", J. Nutr. Biochem., 10: 573-581, 1999.	
	2.	"Inclusion complexation of CoQ-10 with cyclodextrins", Acta Pol. Pharm., 52:379-386, 1995	
	3.	"Investigation of inclusion complexes of CoQ-10 with g-cyclodextrin and methyl-b-cyclodextrin. Part I. Comparison of complexation methods in the solution state", Acta Pol. Pharm., 53: 193-196, 1996a.	
	4.	"Investigation of inclusion complexes of CoQ-10 with g-cyclodextrin and methyl-b-cyclodextrin. Part II. The influence of complexation temperature (heating method) on CoQ-10 solubility", Acta Pol. Pharm., 53: 197-201, 1996b. complexation temperature (heating method) on CoQ-10 solubility", Acta Pol. Pharm., 53: 197-201, 1996b.	
	5.	"Investigation of inclusion complexes of CoQ-10 with g-cyclodextrin and methyl-b-cyclodextrin. Part III. The influence of cyclodextrins on CoQ-10 stability", Acta Pol. Pharm., 54: 279-285, 1997	
	6.	"A moderate interaction of maltosyl-alpha-cyclodextrin with Caco2 cells in comparison with the parent cyclodextrin", Biol. Pharm. Bull., 24: 395-402, 2001.	
	7.	"Uptake and passage of beta lactoglobulin, palmitic acid and retinal across the Caco-2 monolayer", Biochim. Biophys. Acta., 1236: 149-154, 1995.	
	8.	"Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats", Pharm Res. 11: 1174-9, 1994	
	9.	"Intestinal safety of water soluble beta-cyclodextrins in pediatric oral solutions of spironolactone: effects on human epithelial Caco-2 cells", J. Pharm. Pharmacol., 49: 43-8, 1997.	
	10	"Vitamin E uptake by human intestinal cells during lipolysis in vitro", Gastroenterology, 98: 96-103, 1990.	

Examiner Signature		Date Considered	9/20/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

**Complete if Known**

Application Number	10/748,096
Filing Date	December 30, 2003
First Named Inventor	Doddabele L. Madhavi
Art Unit	1623
Examiner Name	Matthew L. Fedowitz
Attorney Docket Number	BIO 2-013

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	11	" <del>Transepithelial transport of putrescine across monolayers of the human</del> intestinal epithelial cell line, Caco2", World J. Gastroenterol., 7: 193-197, 2001.	
	12	" <del>Improvement of dissolution and absorption characteristics of ubidecarenone</del> by dimethyl-b-cyclodextrin complexation", Acta Pharm. Nord., 1: 99-104, 1989.	
	13	" <del>The effect of parenterally administered cyclodextrins on cholesterol</del> levels in the rat", Pharm. Res., 8: 9-16, 1991	
	14	" <del>Studies on the inclusion compound between b-cyclodextrin and cholesterol</del> ", In D. Duchene (Ed), 5th International Symposium on Cyclodextrins, 1990, pp 299-302, Editions de Sante, Paris	
MF	15	"Cyclodextrins as carriers of cholesterol and fatty acids in cultivation of mycoplasmas", Appl. Envr. Microbiol., 59: 547-551, 1993).	
MF	16	"Comparison of impact of the different hydrophilic carriers on the properties of piperazine-containing drug", Eur. J. Pharm. Biopharm., 51: 221-225, 2001.	
	17	" <del>Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state</del> ", J. Pharm. Pharmacol., 45: 1028-32, 1993	
MF	18	"Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state", Int. J. Pharm., 243: 107-17, 2002	
MF	19	"Enhancement of dissolution and oral bioavailability of gliquidone with hydroxypropyl-beta-cyclodextrin", Pharmacia, 2003: 58 (11): 807-10	
MF	20	Physiocochemical characterization and in vitro dissolution behavior of nicardipine hydrochloride inclusion compounds". Eur J Pharm Sci. 2002 Feb; 15(1): 79-88	

Examiner Signature		Date Considered	9/30/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/748,096		
		Filing Date	December 30, 2003		
		First Named Inventor	Doddabele L. Madhavi		
		Art Unit	1623		
		Examiner Name	Matthew L. Fedowitz		
Sheet	4	of	4	Attorney Docket Number	Bio 2-013

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>MF</i>	21	Effect of the hydrophobic nature of triacetyl-b-cyclodextrin on the complexation with nicardipine hydrochloride: physicochemical and dissolution properties of the kneaded and spray-dried complex", Chem Pharm Bull (Tokyo). 2002 Dec; 50 (12): 1597-602	
	22	"Preparation and characterization of albendazole beta-cyclodextrin complexes", Drug Dev Ind Pharm. 1999 Dec; 25(12) :12418	
	23	"Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems", Int J Pharm. 1999 Mar 1; 179(1): 117-28	
	24	"Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins", Int J Pharm. 1999 Dec 20; 193(1): 85-95	
↓	25	"Review-Cyclodextrins in topical drug formulations: Theory and Practice", Int. J. Pharm, 225: 15-30, 2001	

Examiner Signature		Date Considered	9/30/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.